SSTR2 and neuroendocrine neoplasm: In addition, a radionuclide-coupled Sstr2 agonist was recently approved for use as a tumor cell killing therapeutic in mid-gut neuroendocrine tumors, thus creating a clinical precedent for the conjugation of tumor cell killing analogs to Sstr2 agonists (6, 7, 8).